These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 27758044)

  • 21. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
    Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
    J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
    Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
    J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin.
    Han J; Hiebert LM
    Vascul Pharmacol; 2013; 59(3-4):112-8. PubMed ID: 23939434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of heparanase inhibitors for anti-cancer therapy.
    Miao HQ; Liu H; Navarro E; Kussie P; Zhu Z
    Curr Med Chem; 2006; 13(18):2101-11. PubMed ID: 16918340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation.
    Ferro V; Hammond E; Fairweather JK
    Mini Rev Med Chem; 2004 Aug; 4(6):693-702. PubMed ID: 15279603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development.
    Vlodavsky I; Goldshmidt O; Zcharia E; Atzmon R; Rangini-Guatta Z; Elkin M; Peretz T; Friedmann Y
    Semin Cancer Biol; 2002 Apr; 12(2):121-9. PubMed ID: 12027584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Good and Bad Sides of Heparanase-1 and Heparanase-2.
    Pinhal MAS; Melo CM; Nader HB
    Adv Exp Med Biol; 2020; 1221():821-845. PubMed ID: 32274740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?
    Li JP
    Anticancer Agents Med Chem; 2008 Jan; 8(1):64-76. PubMed ID: 18220506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Versatile role of heparanase in inflammation.
    Goldberg R; Meirovitz A; Hirshoren N; Bulvik R; Binder A; Rubinstein AM; Elkin M
    Matrix Biol; 2013 Jun; 32(5):234-240. PubMed ID: 23499528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation.
    Teixeira FCOB; Götte M
    Adv Exp Med Biol; 2020; 1221():97-135. PubMed ID: 32274708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
    Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
    Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The heparanase system and tumor metastasis: is heparanase the seed and soil?
    Arvatz G; Shafat I; Levy-Adam F; Ilan N; Vlodavsky I
    Cancer Metastasis Rev; 2011 Jun; 30(2):253-68. PubMed ID: 21308479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.
    Zhao H; Liu H; Chen Y; Xin X; Li J; Hou Y; Zhang Z; Zhang X; Xie C; Geng M; Ding J
    Cancer Res; 2006 Sep; 66(17):8779-87. PubMed ID: 16951194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
    Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
    Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparanase: a target for drug discovery in cancer and inflammation.
    McKenzie EA
    Br J Pharmacol; 2007 May; 151(1):1-14. PubMed ID: 17339837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate.
    Escobar Galvis ML; Jia J; Zhang X; Jastrebova N; Spillmann D; Gottfridsson E; van Kuppevelt TH; Zcharia E; Vlodavsky I; Lindahl U; Li JP
    Nat Chem Biol; 2007 Dec; 3(12):773-8. PubMed ID: 17952066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells.
    Jiang G; Zheng L; Pu J; Mei H; Zhao J; Huang K; Zeng F; Tong Q
    PLoS One; 2012; 7(2):e31379. PubMed ID: 22363633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.
    Levy-Adam F; Feld S; Cohen-Kaplan V; Shteingauz A; Gross M; Arvatz G; Naroditsky I; Ilan N; Doweck I; Vlodavsky I
    J Biol Chem; 2010 Sep; 285(36):28010-9. PubMed ID: 20576607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumorigenic and adhesive properties of heparanase.
    Levy-Adam F; Ilan N; Vlodavsky I
    Semin Cancer Biol; 2010 Jun; 20(3):153-60. PubMed ID: 20619346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.